covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | October 7, 2020 | News story | Research and Development COVID, COVID-19, corornavirus 

The coronavirus news this week focuses on treatments, with Enlivex Therapeutics releasing positive data for its therapy Allocetra as a treatment for patients with severe forms of the virus, while Remdesivir has a “favourable” benefit/risk profile in COVID-19, a DSRU review argues.

In other news, Russia is sowing disinformation about COVID-19 vaccines to undermine inoculation efforts in Western aligned countries, according to a top UK military official, and India’s largest contract tracing study has found that the virus has been transmitted through ‘super spreaders.’

1. Enlivex’s Allocetra improves COVID-19 recovery times, early data show – Published on 01/10/20

Israeli immunotherapy firm Enlivex Therapeutics has released tentatively positive data for its therapy Allocetra as a treatment for patients with severe and critical forms of COVID-19.

2. Russia is spreading lies about COVID-19 vaccines, alleges UK Chief of Defence Staff– Published on 01/10/20

Russia is sowing disinformation about COVID-19 vaccines to undermine inoculation efforts in Western aligned countries, according to a top UK military official.

3. White House halts release of new FDA standards for the Emergency Use Authorization of COVID-19 vaccine – Published on 06/10/20

The Trump White House is blocking new federal guidance for the emergency release of coronavirus vaccines that would essentially ensure none would be approved before the presidential election.

4. Coronavirus transmission in India driven by superspreaders – Published on 01/10/20

India’s largest contract tracing study has found that the virus has been transmitted through ‘super spreaders.’

5. Remdesivir has a “favourable” benefit/risk profile in COVID-19 but more data needed, DSRU review argues – Published on 05/10/20

Southampton’s Drug Safety Research Unit (DSRU) has released a systematic benefit/risk analysis of Gilead’s antiviral drug remdesivir in the treatment of COVID-19, published in Drug Safety.

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content